The purpose of this study was to evaluate the efficacy and compliance of tailored therapy which using the polymerase chain reaction for point mutation of clarithromycin, compared to concomitant therapy, in patients without history of H. pylori eradication.

NCT03130452

Conditions

1. Helicobacter Pylori Infection

Interventions

1. Drug: Lansoprazole 30mg
2. Drug: Amoxicillin 1.0g Tab
3. Drug: Clarithromycin 500mg
4. Drug: Metronidazole 500 mg

Method> Patients with H. pylori infection who have been screened for a 23S ribosomal RNA point mutation (A2142G, A2143G point mutation) and randomized to a concomitant treatment group and a tailored treatment group. --- A2142G ---

The investigators investigated the point mutations in the 23S rRNA genes of patients infected with clarithromycin-resistant H. pylori and compared the H. pylori eradication rates based on the identified clinically significant point mutations.

NCT03884348

Conditions

1. Helicobacter Pylori Infection
2. Antibiotic Resistant Strain

Interventions

1. Drug: proton pump inhibitor, amoxicillin, clarithromycin
2. Drug: proton pump inhibitor, amoxicillin, metronidazole

MeSH:Sprains and Strains

Inclusion Criteria: - Clinical diagnosis of Helicobacter pylori infection Exclusion Criteria: - H. pylori eradication therapy within 1 year, - antibiotics within 4 weeks, - surgery for gastric cancer - malignant tumors other than gastric cancer - end-stage renal disease - liver cirrhosis, - pregnancy Inclusion Criteria: - Clinical diagnosis of Helicobacter pylori infection Exclusion Criteria: - H. pylori eradication therapy within 1 year, - antibiotics within 4 weeks, - surgery for gastric cancer - malignant tumors other than gastric cancer - end-stage renal disease - liver cirrhosis, - pregnancy Helicobacter Pylori Infection Antibiotic Resistant Strain Sprains and Strains Sequencing-based detection of point mutations identified four mutations that were considered clinically significant (A2142G, A2142C, A2143G, A2143C), while all the other mutations were considered clinically insignificant. --- A2142G ---

We aimed to compare the efficacy of genotypic resistance-guided tailored therapy vs empirical therapy for eradication of Helicobacter pylori (H. pylori) infection in randomized controlled trials.

NCT04006340

Conditions

1. Helicobacter Pylori 23S rRNA Clarithromycin Resistance Mutation
2. Helicobacter Pylori Infection

Interventions

1. Combination Product: triple therapy
2. Combination Product: quadruple therapy
3. Diagnostic Test: dual-priming oligonucleotide-based multiplex (DPO)-PCR test

MeSH:Infection Communicable Diseases Helicobacter Infections

This is a method to confirm the mutation of A2142G and A2143G by PCR, which are known to be highly related to the resistance of clarithromycin 23S rRNA point mutation. --- A2142G ---